Analysts Set ADMA Biologics, Inc. (NASDAQ:ADMA) PT at $7.88

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) have been given a consensus recommendation of “Buy” by the four research firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $7.88.

Several research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $7.50 price target (up previously from $6.00) on shares of ADMA Biologics in a research note on Tuesday, March 26th. Cantor Fitzgerald raised their price objective on shares of ADMA Biologics from $6.50 to $8.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Mizuho upped their target price on ADMA Biologics from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, March 1st.

Insider Activity at ADMA Biologics

In other news, Director Steve Elms sold 183,008 shares of the firm’s stock in a transaction on Friday, March 15th. The stock was sold at an average price of $6.01, for a total transaction of $1,099,878.08. Following the sale, the director now owns 2,577,387 shares in the company, valued at $15,490,095.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 639,895 shares of company stock valued at $3,927,169. Company insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Stephens Consulting LLC purchased a new position in ADMA Biologics during the third quarter worth approximately $36,000. Cambridge Investment Research Advisors Inc. increased its stake in ADMA Biologics by 31.3% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 15,000 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 3,572 shares during the last quarter. Sawgrass Asset Management LLC purchased a new position in shares of ADMA Biologics in the 3rd quarter worth about $55,000. DekaBank Deutsche Girozentrale purchased a new position in shares of ADMA Biologics in the 3rd quarter worth about $58,000. Finally, Commonwealth Equity Services LLC lifted its stake in shares of ADMA Biologics by 61.8% in the 3rd quarter. Commonwealth Equity Services LLC now owns 16,360 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 6,250 shares in the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Performance

Shares of ADMA opened at $6.81 on Wednesday. The company has a quick ratio of 1.69, a current ratio of 5.16 and a debt-to-equity ratio of 1.04. ADMA Biologics has a 52-week low of $3.06 and a 52-week high of $6.81. The company has a 50-day simple moving average of $6.21 and a 200-day simple moving average of $4.99. The company has a market capitalization of $1.55 billion, a PE ratio of -52.38 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.02. ADMA Biologics had a negative net margin of 10.94% and a positive return on equity of 0.49%. The company had revenue of $73.90 million during the quarter, compared to the consensus estimate of $73.50 million. Equities research analysts predict that ADMA Biologics will post 0.3 earnings per share for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.